BG102947A - Йонни конюгати със забавено освобождаване - Google Patents

Йонни конюгати със забавено освобождаване

Info

Publication number
BG102947A
BG102947A BG102947A BG10294798A BG102947A BG 102947 A BG102947 A BG 102947A BG 102947 A BG102947 A BG 102947A BG 10294798 A BG10294798 A BG 10294798A BG 102947 A BG102947 A BG 102947A
Authority
BG
Bulgaria
Prior art keywords
congguates
ionian
exemption
freedom
sustained release
Prior art date
Application number
BG102947A
Other languages
English (en)
Inventor
Francis Ignatious
Thomas LOUGHMAN
Shalaby SHALABY
Franck Touraud
Original Assignee
Kinerton Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinerton Limited filed Critical Kinerton Limited
Publication of BG102947A publication Critical patent/BG102947A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y10T428/2985—Solid-walled microcapsule from synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Detergent Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Steroid Compounds (AREA)
  • Lubricants (AREA)
  • Fire-Extinguishing Compositions (AREA)

Abstract

Изобретението се отнася до фармацевтични форми найонни конюгати със забавено освобождаване, включващи биоразграждащи се полимери на база свободна карбоксилна група и лекарствени вещества със свободна аминогрупа, свързани един с друг чрез йонна връзка. Изобретението се отнася и до метод за получаването на йонните конюгати.
BG102947A 1996-04-23 1998-11-23 Йонни конюгати със забавено освобождаване BG102947A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE960308A IE960308A1 (en) 1996-04-23 1996-04-23 Sustained release ionic conjugate
PCT/IE1997/000030 WO1997039738A2 (en) 1996-04-23 1997-04-22 Sustained release ionic conjugate

Publications (1)

Publication Number Publication Date
BG102947A true BG102947A (bg) 1999-08-31

Family

ID=11041150

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102947A BG102947A (bg) 1996-04-23 1998-11-23 Йонни конюгати със забавено освобождаване

Country Status (27)

Country Link
US (3) US6911218B2 (bg)
EP (1) EP0904062B1 (bg)
JP (2) JP3390177B2 (bg)
KR (1) KR20000010621A (bg)
CN (2) CN1186012C (bg)
AT (1) ATE245970T1 (bg)
BG (1) BG102947A (bg)
BR (1) BR9708818A (bg)
CA (1) CA2252826A1 (bg)
CZ (2) CZ293965B6 (bg)
DE (1) DE69723833T2 (bg)
DK (1) DK0904062T3 (bg)
EE (1) EE9800349A (bg)
ES (1) ES2200172T3 (bg)
HU (1) HU224036B1 (bg)
IE (1) IE960308A1 (bg)
IL (1) IL126619A (bg)
IS (1) IS4869A (bg)
NO (1) NO984924L (bg)
NZ (1) NZ332893A (bg)
PL (2) PL188517B1 (bg)
PT (1) PT904062E (bg)
RU (1) RU2173137C2 (bg)
SK (1) SK145598A3 (bg)
TR (1) TR199802125T2 (bg)
WO (1) WO1997039738A2 (bg)
YU (1) YU46598A (bg)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221958B1 (en) * 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US6413539B1 (en) * 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
IE960308A1 (en) * 1996-04-23 1997-11-05 Kinerton Ltd Sustained release ionic conjugate
US6867181B1 (en) 1997-06-02 2005-03-15 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US6486214B1 (en) 1997-09-10 2002-11-26 Rutgers, The State University Of New Jersey Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
US7122615B1 (en) 1998-09-10 2006-10-17 Rutgers, The State University Of New Jersey Polyanhydrides with therapeutically useful degradation products
US6468519B1 (en) 1997-09-10 2002-10-22 Rutgers, The State University Of New Jersey Polyanhydrides with biologically active degradation products
EP1240896A3 (en) * 1998-07-23 2003-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Encapsulation of water soluble peptides
EP1348444B1 (en) * 1999-08-18 2006-04-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Sustained release formulation of a peptide complexed with a polymer
AU767837B2 (en) * 1999-08-18 2003-11-27 Ipsen Pharma S.A.S. Sustained release formulation of a peptide
US7109166B1 (en) 1999-08-18 2006-09-19 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Sustained release formulation of a peptide
IES990700A2 (en) * 1999-08-18 2001-08-22 Kinerton Ltd Process to make a sustained release formulation
US20040038948A1 (en) 1999-12-07 2004-02-26 Uhrich Kathryn E. Therapeutic compositions and methods
US6685928B2 (en) 1999-12-07 2004-02-03 Rutgers, The State University Of New Jersey Therapeutic compositions and methods
KR100452752B1 (ko) * 2000-04-18 2004-10-12 주식회사 펩트론 단백질 함유 서방성 제제를 제조하는 방법 및 그 제제
EP1309354A2 (en) 2000-07-27 2003-05-14 Rutgers, The State University Therapeutic polyesters and polyamides
AU2001279064A1 (en) 2000-07-27 2002-02-13 Rutgers, The State University Therapeutic azo-compounds for drug delivery
CN1646068A (zh) 2002-02-07 2005-07-27 拉特格斯,新泽西州立大学 治疗用的聚酯和聚酰胺
WO2003090807A1 (en) * 2002-04-24 2003-11-06 Poly-Med, Inc. Multifaceted endovascular stent coating for preventing restenosis
AU2003289178A1 (en) * 2002-12-04 2004-06-23 Yasuo Hatate Agricultural-chemical microcapsule preparation made by oil/oil liquid drying and process for producing the same
MX2007004676A (es) 2004-10-27 2007-11-14 Univ Denver Analogos de la hormona adrenocorticotropica y metodos relacionados.
EP1951260A4 (en) 2005-10-21 2009-11-11 Bezwada Biomedical Llc FUNCTIONALIZED PHENOLIC COMPOUNDS AND POURABLE ARTICLES THEREOF
US8007526B2 (en) 2005-12-01 2011-08-30 Bezwada Biomedical, Llc Difunctionalized aromatic compounds and polymers therefrom
WO2008034019A2 (en) 2006-09-13 2008-03-20 Polymerix Corporation Active agents and their oligomers and polymers
HUE026001T2 (en) 2007-02-05 2016-04-28 Apellis Pharmaceuticals Inc Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
PE20090387A1 (es) 2007-05-24 2009-04-28 Novartis Ag Formulacion de pasireotida
US8217134B2 (en) 2007-08-30 2012-07-10 Bezwada Biomedical, Llc Controlled release of biologically active compounds
US8048980B2 (en) 2007-09-17 2011-11-01 Bezwada Biomedical, Llc Hydrolysable linkers and cross-linkers for absorbable polymers
KR101224004B1 (ko) * 2009-12-29 2013-01-22 주식회사 삼양바이오팜 단백질, 폴리펩타이드 또는 펩타이드 약물 전달용 고분자 및 그 제조방법, 및 단백질, 폴리펩타이드 또는 펩타이드 약물의 서방형 조성물 및 그 제조 방법
US9144579B2 (en) 2012-08-17 2015-09-29 Rutgers, The State University Of New Jersey Polyesters and methods of use thereof
US20140120057A1 (en) 2012-10-25 2014-05-01 Rutgers, The State University Of New Jersey Polymers and methods thereof for wound healing
US9387250B2 (en) 2013-03-15 2016-07-12 Rutgers, The State University Of New Jersey Therapeutic compositions for bone repair
WO2014194055A1 (en) 2013-05-29 2014-12-04 Rutgers, The State University Of New Jersey Antioxidant-based poly(anhydride-esters)
US10023521B2 (en) 2014-06-13 2018-07-17 Rutgers, The State University Of New Jersey Process and intermediates for preparing poly(anhydride-esters)
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
WO2016164898A1 (en) 2015-04-10 2016-10-13 Rutgers, The State University Of New Jersey Kojic acid polymers
CA3193527A1 (en) 2020-10-28 2022-05-05 Yoshitaka Aoyama Projection nut feeder

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS5933214A (ja) 1982-08-19 1984-02-23 Mitsui Toatsu Chem Inc 微小球に製剤された制ガン剤の製造方法
DE3936191C2 (de) 1989-10-31 1996-10-17 Boehringer Ingelheim Kg Neue Copolymere aus Milchsäure und Weinsäure, ihre Herstellung sowie ihre Verwendung
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
JP2653255B2 (ja) 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
DE4034334A1 (de) 1990-10-29 1992-04-30 Basf Ag Verwendung von weinsaeure einkondensiert enthaltenden polyestern als waschmittelzusatz, verfahren zur herstellung der polyester und polyester aus weinsaeure und tetracarbonsaeuren
ZA93929B (en) * 1992-02-18 1993-09-10 Akzo Nv A process for the preparation of biologically active materialcontaining polymeric microcapsules.
DE69311538D1 (de) * 1992-03-12 1997-07-17 Alkermes Inc Acth enthaltende mikrokugeln mit gesteuerter abgabe
AU4923793A (en) 1992-09-22 1994-04-12 Biopak Technology, Ltd. Degradation control of environmentally degradable disposable materials
DK0678018T3 (da) * 1993-01-06 2003-04-28 Kinerton Ltd Ion molekylærkonjugater af bionedbrydelige polyestere og bioaktive polypeptider
US6221958B1 (en) 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
GB9310030D0 (en) 1993-05-15 1993-06-30 Scras Dry processed particles and process for the preparation of the same
EP2283821A1 (en) 1993-11-19 2011-02-16 Alkermes, Inc. Preparation of biodegradable microparticles containing a biologically active agent
IE960308A1 (en) * 1996-04-23 1997-11-05 Kinerton Ltd Sustained release ionic conjugate
WO1997040085A2 (en) 1996-04-23 1997-10-30 Kinerton Limited Acidic polylactic polymers

Also Published As

Publication number Publication date
HK1018748A1 (zh) 2000-01-07
US7026431B2 (en) 2006-04-11
HU224036B1 (hu) 2005-05-30
KR20000010621A (ko) 2000-02-25
DE69723833T2 (de) 2004-05-13
WO1997039738A3 (en) 1997-11-27
IL126619A0 (en) 1999-08-17
JPH11508609A (ja) 1999-07-27
SK145598A3 (en) 1999-03-12
HUP0000122A3 (en) 2000-08-28
DK0904062T3 (da) 2003-10-20
AU2575197A (en) 1997-11-12
CN1626243A (zh) 2005-06-15
CZ293822B6 (cs) 2004-08-18
RU2173137C2 (ru) 2001-09-10
CZ329998A3 (cs) 1999-02-17
US6911218B2 (en) 2005-06-28
JP3390177B2 (ja) 2003-03-24
WO1997039738A2 (en) 1997-10-30
ES2200172T3 (es) 2004-03-01
EP0904062A2 (en) 1999-03-31
EE9800349A (et) 1999-04-15
US20060121120A1 (en) 2006-06-08
NO984924L (no) 1998-12-21
PT904062E (pt) 2003-11-28
PL329606A1 (en) 1999-03-29
CZ293965B6 (cs) 2004-08-18
US7179490B2 (en) 2007-02-20
CN1216465A (zh) 1999-05-12
HUP0000122A2 (hu) 2000-06-28
BR9708818A (pt) 2000-01-04
YU46598A (sh) 1999-09-27
IE960308A1 (en) 1997-11-05
TR199802125T2 (xx) 1999-01-18
PL189319B1 (pl) 2005-07-29
NO984924D0 (no) 1998-10-22
AU721433B2 (en) 2000-07-06
ATE245970T1 (de) 2003-08-15
NZ332893A (en) 2000-03-27
IS4869A (is) 1998-10-16
EP0904062B1 (en) 2003-07-30
JP2003026606A (ja) 2003-01-29
US20050074492A1 (en) 2005-04-07
PL188517B1 (pl) 2005-02-28
DE69723833D1 (de) 2003-09-04
CA2252826A1 (en) 1997-10-30
IL126619A (en) 2003-07-31
CN1186012C (zh) 2005-01-26
US20020041893A1 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
BG102947A (bg) Йонни конюгати със забавено освобождаване
ATE399185T1 (de) Maleinsäureamid polymerderivate und ihre biokonjugate
BR0210179A (pt) Compostos analgésicos de liberação sustentada
FI20050932A7 (fi) Heterobifunktionaaliset polymeeriset biokonjugaatit
IL135148A0 (en) A polysaccharide conjugate and pharmaceutical compositions containing the same
NO20002547D0 (no) Poly(vinylamin)-baserte superabsorberende geler og fremgangsmÕte for fremstilling derav
ATE369878T1 (de) Träger-pharmaka-konjugate
TR200101751T2 (tr) Poliol-IFN-beta konjugatları
EA199800946A1 (ru) Концентрированный препарат антител
ATE261310T1 (de) Nicht-antigene von aminen abgeleitete polymere und polymerkonjugate
ATE263579T1 (de) Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel
BR9915198A (pt) Composto dds e método para medição do mesmo
ATE332918T1 (de) Neoglycoproteine
DK0973819T3 (da) Ikke-antigene forgrenede polymerkonjugater
DE69903351D1 (de) Vernetzte hyaluronsäure und ihre medizinischen verwendungen
DK0971717T3 (da) Cytotoksiske aminosukker- og relaterede sukkerderivater af indolopyrrolocarbazoler
AR010554A1 (es) Composiciones solidas que comprenden calcitonina, o un conjugado o un fragmento de la misma, metodo para su preparacion. preparacion farmaceuticaoral, preparacion bucal, comprimido de fusion rapida, y solucion homogenea.
ATE331037T1 (de) Isoliertes frpb nukleinsäuremolekül und entsprechende impfstoff
DK0975334T3 (da) Biologisk nedbrydelige mikropartikler til langvarig frigivelse af terapeutiske midler
UA82983C2 (ru) Полимерные коньюгаты найбластина и способы их использования
ATE280588T1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
CY1105235T1 (el) Συνθεσεις λασοφοξιφενης
ATE203665T1 (de) Stabilisierte pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung
NO972531L (no) Nye membranproteiner p76 av Helicobacter pylori
ATE254469T1 (de) Verfahren zur verminderung der renalen aufnahme von antikörperfragmenten